Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jared M Odegard

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal for Immunotherapy of Cancer|April 11, 2024
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumorsJared M Odegard, Ahmed A Othman, Kai-Wen Lin, et al.
Frontiers in Immunology|December 19, 2025
CD47 expression in solid tumors correlates with phagocytic tumor-associated macrophage gene signatureNicholas van Buuren, Mengshu Xu, Yi Zhang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2014
Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cellsSemih U Tareen, Brenna Kelley-Clarke, Christopher J Nicolai, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2015
Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapyJared M Odegard, Brenna Kelley-Clarke, Semih U Tareen, et al.
JCI Insight|November 1, 2019
A composite immune signature parallels disease progression across T1D subjectsCate Speake, Samuel O Skinner, Dror Berel, et al.
Diabetologia|December 3, 2017
Combinatorial detection of autoreactive CD8<sup>+</sup> T cells with HLA-A2 multimers: a multi-centre study by the Immunology of Diabetes Society T Cell WorkshopEddie A James, Joana R F Abreu, John W McGinty, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2026
Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis BEdward J Gane, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal for Immunotherapy of Cancer|April 11, 2024
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumorsJared M Odegard, Ahmed A Othman, Kai-Wen Lin, et al.
Frontiers in Immunology|December 19, 2025
CD47 expression in solid tumors correlates with phagocytic tumor-associated macrophage gene signatureNicholas van Buuren, Mengshu Xu, Yi Zhang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2014
Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cellsSemih U Tareen, Brenna Kelley-Clarke, Christopher J Nicolai, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2015
Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapyJared M Odegard, Brenna Kelley-Clarke, Semih U Tareen, et al.
JCI Insight|November 1, 2019
A composite immune signature parallels disease progression across T1D subjectsCate Speake, Samuel O Skinner, Dror Berel, et al.
Diabetologia|December 3, 2017
Combinatorial detection of autoreactive CD8<sup>+</sup> T cells with HLA-A2 multimers: a multi-centre study by the Immunology of Diabetes Society T Cell WorkshopEddie A James, Joana R F Abreu, John W McGinty, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2026
Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis BEdward J Gane, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Pageof 2